Chronic inflammation and cancer: Suppressing the suppressors

Cancer Immunology, Immunotherapy

Volumn 63, Issue 1, 2014, Pages 11-20

  Baniyash, Michal ^a   Sade Feldman, Moshe ^a   Kanterman, Julia ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Anti cancer therapy; Cancer; Chronic inflammation; CITIM 2013; Immunosuppression; Myeloid derived suppressor cells

Indexed keywords

CANCER VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL EXPANSION; CELL TRANSFER; CHRONIC INFLAMMATION; HUMAN; NEOPLASM; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SUPPRESSOR CELL;

EID: 84891866719     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1468-9     Document Type: Review

References (50)

1. Baniyash M (2004) TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 4(9):675-687. doi: 10.1038/nri1434 (Pubitemid 39223074)
2. Ciszak L, Pawlak E, Kosmaczewska A, Potoczek S, Frydecka I (2007) Alterations in the expression of signal-transducing CD3 zeta chain in T cells from patients with chronic inflammatory/autoimmune diseases. Arch Immunol Ther Exp (Warsz) 55(6):373-386. doi: 10.1007/s00005-007-0042-6
3. Vaknin I, Blinder L, Wang L, Gazit R, Shapira E, Genina O, Pines M, Pikarsky E, Baniyash M (2008) A common pathway mediated through Toll-like receptors leads to T- and natural killer-cell immunosuppression. Blood 111(3):1437-1447. doi: 10.1182/blood-2007-07-100404 (Pubitemid 351213431)
4. Bronstein-Sitton N, Cohen-Daniel L, Vaknin I, Ezernitchi AV, Leshem B, Halabi A, Houri-Hadad Y, Greenbaum E, Zakay-Rones Z, Shapira L, Baniyash M (2003) Sustained exposure to bacterial antigen induces interferon-gamma- dependent T cell receptor zeta down-regulation and impaired T cell function. Nat Immunol 4(10):957-964. doi: 10.1038/ni975 (Pubitemid 37270574)
5. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162-174. doi: 10.1038/nri2506
6. Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S (2009) Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol 85(6):996-1004. doi: 10.1189/jlb.0708446
7. Sade-Feldman M, Kanterman J, Ish-Shalom E, Elnekave M, Horwitz E, Baniyash M (2013) Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 38(3):541-554. doi: 10.1016/j.immuni.2013.02.007
8. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S (2006) Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 176(1):284-290. doi: 10.1189/jlb.0708446 (Pubitemid 43023273)
9. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I (2004) High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 64(17):6337-6343. doi: 10.1158/0008-5472.CAN-04-0757 (Pubitemid 39129439)
10. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, Moses HL (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13(1):23-35. doi: 10.1016/j.ccr.2007.12.004 (Pubitemid 350309741)
11. Zhao X, Rong L, Li X, Liu X, Deng J, Wu H, Xu X, Erben U, Wu P, Syrbe U, Sieper J, Qin Z (2012) TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Investig 122(11):4094-4104. doi: 10.1172/JCI64115
12. Srivastava MK, Andersson A, Zhu L, Harris-White M, Lee JM, Dubinett S, Sharma S (2012) Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy 4(3):291-304. doi: 10.2217/imt.11.178
13. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72(9):3666-3670
14. Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9(5):361-371. doi: 10.1038/nrc2628
15. Thompson AE, Rieder SW, Pope JE (2011) Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 63(6):1479-1485. doi: 10.1002/art.30310
16. Kopylov U, Ben-Horin S, Zmora O, Eliakim R, Katz LH (2012) Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis. Inflamm Bowel Dis 18(12):2404-2413. doi: 10.1002/ibd.22954
17. Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, Borrello I, Kato M, Schadendorf D, Baniyash M, Umansky V (2011) Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA 108(41):17111-17116. doi: 10.1073/pnas.1108121108
18. Talmadge JE (2007) Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 13(18 Pt 1):5243-5248. doi: 10.1158/1078-0432.CCR-07- 0182 (Pubitemid 47510346)
19. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V (2008) Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222:162-179. doi: 10.1111/j.1600-065X.2008.00602.x (Pubitemid 351430364)
20. Martin F, Apetoh L, Ghiringhelli F (2012) Role of myeloid-derived suppressor cells in tumor immunotherapy. Immunotherapy 4(1):43-57. doi: 10.2217/imt.11.154
21. Kanterman J, Sade-Feldman M, Baniyash M (2012) New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol 22(4):307-318. doi: 10.1016/j.semcancer.2012.02.008
22. Fujimura T, Mahnke K, Enk AH (2010) Myeloid derived suppressor cells and their role in tolerance induction in cancer. J Dermatol Sci 59(1):1-6. doi: 10.1016/j.jdermsci.2010.05.001
23. Apetoh L, Vegran F, Ladoire S, Ghiringhelli F (2011) Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies. Curr Mol Med 11(5):365-372. doi: 10.1016/j.molmed.2008.02.002
24. Kodumudi KN, Weber A, Sarnaik AA, Pilon-Thomas S (2012) Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol 189(11):5147-5154. doi: 10.4049/jimmunol.1200274
25. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G (2008) The anticancer immune response: indispensable for therapeutic success? J Clin Investig 118(6):1991-2001. doi: 10.1172/JCI35180 (Pubitemid 351872317)
26. Srivastava MK, Zhu L, Harris-White M, Kar UK, Huang M, Johnson MF, Lee JM, Elashoff D, Strieter R, Dubinett S, Sharma S (2012) Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 7(7):e40677. doi: 10.1371/journal.pone.0040677
27. Najjar YG, Finke JH (2013) Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol 3:49. doi: 10.3389/fonc.2013.00049
28. Youn JI, Gabrilovich DI (2010) The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 40(11):2969-2975. doi: 10.1002/eji.201040895
29. Wang L, Chang EW, Wong SC, Ong SM, Chong DQ, Ling KL (2013) Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol 190(2):794-804. doi: 10.4049/jimmunol.1202088
30. van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E, Hoekman K, de Gruijl TD (2008) Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res 14(18):5884-5892. doi: 10.1158/1078-0432.CCR-08-0656
31. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15(6):2148-2157. doi: 10.1158/1078-0432.CCR- 08-1332
32. Bose A, Lowe DB, Rao A, Storkus WJ (2012) Combined vaccine + axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res 22(3):236-243. doi: 10.1097/CMR.0b013e3283538293
33. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rebe C, Ghiringhelli F (2010) 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 70(8):3052-3061. doi: 10.1158/0008-5472.CAN-09-3690
34. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM (2005) Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11(18):6713-6721. doi: 10.1158/1078-0432.CCR-05-0883 (Pubitemid 41339014)
35. Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD (2009) Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 9(7-8):900-909. doi: 10.1016/j.intimp.2009.03.015
36. Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, Vegran F, Boireau W, Simon B, Ryffel B, Connat JL, Kanellopoulos J, Martin F, Rebe C, Apetoh L, Ghiringhelli F (2013) Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 19(1):57-64. doi: 10.1038/nm.2999
37. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H (2005) Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105(7):2862-2868. doi: 10.1182/blood-2004-06-2410 (Pubitemid 40446280)
38. Sevko A, Sade-Feldman M, Kanterman J, Michels T, Falk CS, Umansky L, Ramacher M, Kato M, Schadendorf D, Baniyash M, Umansky V (2013) Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Investig Dermatol 133(6):1610-1619. doi: 10.1038/jid.2012.444
39. Liu Y, Kosaka A, Ikeura M, Kohanbash G, Fellows-Mayle W, Snyder LA, Okada H (2013) Premetastatic soil and prevention of breast cancer brain metastasis. Neuro Oncol 15(7):891-903. doi: 10.1093/neuonc/not031
40. Ma C, Kapanadze T, Gamrekelashvili J, Manns MP, Korangy F, Greten TF (2012) Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol 92(6):1199-1206. doi: 10.1189/jlb.0212059
41. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG, Hegmans JP (2010) COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 10:464. doi: 10.1186/1471-2407- 10-464
42. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I (2006) Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203(12):2691-2702. doi: 10.1084/jem.20061104 (Pubitemid 44833345)
43. Zhou J, Wu J, Chen X, Fortenbery N, Eksioglu E, Kodumudi KN, Pk EB, Dong J, Djeu JY, Wei S (2011) Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions. Int Immunopharmacol 11(7):890-898. doi: 10.1016/j.intimp.2011.01.007
44. Chen SR, Xu XZ, Wang YH, Chen JW, Xu SW, Gu LQ, Liu PQ (2010) Icariin derivative inhibits inflammation through suppression of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways. Biol Pharm Bull 33(8):1307-1313. doi: 10.1242/dev.089052
45. Schilling B, Sucker A, Griewank K, Zhao F, Weide B, Gorgens A, Giebel B, Schadendorf D, Paschen A (2013) Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer 133:1653-1664. doi: 10.1002/ijc.28168
46. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58(1):49-59. doi: 10.1007/s00262-008-0523-4
47. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI (2006) All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 66(18):9299-9307. doi: 10.1158/0008-5472.CAN-06-1690 (Pubitemid 44521152)
48. Michels T, Shurin GV, Naiditch H, Sevko A, Umansky V, Shurin MR (2012) Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J Immunotoxicol 9(3):292-300. doi: 10.3109/1547691X.2011.642418
49. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY (2010) A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 16(18):4583-4594. doi: 10.1158/1078-0432.CCR-10-0733
50. Djeu J, Wei S (2012) Chemoimmunomodulation of MDSCs as a novel strategy for cancer therapy. Oncoimmunology 1(1):121-122. doi: 10.4161/onci.1.1.18074